101 related articles for article (PubMed ID: 2569929)
41. Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas.
Pan BF; Nelson JA
Cancer Chemother Pharmacol; 2007 Apr; 59(5):697-702. PubMed ID: 17009030
[TBL] [Abstract][Full Text] [Related]
42. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
Sato A; Montgomery JA; Cory JG
Cancer Res; 1984 Aug; 44(8):3286-90. PubMed ID: 6611198
[TBL] [Abstract][Full Text] [Related]
43. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
44. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats.
Gandhi V; Chen W; Ayres M; Rhie JK; Madden TL; Newman RA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):85-94. PubMed ID: 12172971
[TBL] [Abstract][Full Text] [Related]
45. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Carson DA; Wasson DB; Taetle R; Yu A
Blood; 1983 Oct; 62(4):737-43. PubMed ID: 6136305
[TBL] [Abstract][Full Text] [Related]
46. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.
Carson DA; Wasson DB; Kaye J; Ullman B; Martin DW; Robins RK; Montgomery JA
Proc Natl Acad Sci U S A; 1980 Nov; 77(11):6865-9. PubMed ID: 6256765
[TBL] [Abstract][Full Text] [Related]
47. Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine.
Carson DA; Kaye J; Seegmiller JE
J Immunol; 1978 Nov; 121(5):1726-31. PubMed ID: 309480
[No Abstract] [Full Text] [Related]
48. 2'-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2'-deoxyadenosine resistance in lymphoid cell lines.
Orr RM; Talbot DC; Aherne WG; Fisher TC; Serafinowski P; Harrap KR
Clin Cancer Res; 1995 Apr; 1(4):391-8. PubMed ID: 9815996
[TBL] [Abstract][Full Text] [Related]
49. Selective toxicity of deoxyadenosine analogues in human melanoma cell lines.
Parsons PG; Bowman EP; Blakley RL
Biochem Pharmacol; 1986 Nov; 35(22):4025-9. PubMed ID: 2430574
[TBL] [Abstract][Full Text] [Related]
50. On the paradoxically concentration-dependent metabolism of 6-mercaptopurine in WEHI-3b murine leukemia cells.
Liliemark J; Pettersson B; Engberg B; Lafolie P; Masquelier M; Peterson C
Cancer Res; 1990 Jan; 50(1):108-12. PubMed ID: 2293545
[TBL] [Abstract][Full Text] [Related]
51. Antineoplastic effect of the combination of 2,3-dihydro-1H-pyrazole[2,3a]imidazole plus deoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl)adenine in mice with L1210 leukemia cells.
Matsumoto M; Weckbecker G; Cory JG
Cancer Commun; 1990; 2(1):1-6. PubMed ID: 2369548
[TBL] [Abstract][Full Text] [Related]
52. [nhibitory effect of adenosine analogues on invasion of human ovarian cancer cell line HO-8910PM].
Zhu F; Liu XG; Liang NC
Ai Zheng; 2004 Dec; 23(12):1646-50. PubMed ID: 15601553
[TBL] [Abstract][Full Text] [Related]
53. Mechanism of cytotoxicity of 2-chloro and 2-bromodeoxyadenosine for a human lymphoblastic cell line, CCRF-CEM.
Blakley RL; Huang MC; Ashmun RA; Koob R
Adv Exp Med Biol; 1986; 195 Pt B():589-93. PubMed ID: 3490127
[No Abstract] [Full Text] [Related]
54. Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Adv Enzyme Regul; 1983; 21():259-70. PubMed ID: 6400064
[TBL] [Abstract][Full Text] [Related]
55. Improved synthesis and antitumor activity of 2-bromo-2'-deoxyadenosine.
Huang MC; Avery TL; Blakley RL; Secrist JA; Montgomery JA
J Med Chem; 1984 Jun; 27(6):800-2. PubMed ID: 6610764
[TBL] [Abstract][Full Text] [Related]
56. Metabolic activation of 2,6-diaminopurine and 2,6-diaminopurine-2'-deoxyriboside to antitumor agents.
Weckbecker G; Cory JG
Adv Enzyme Regul; 1989; 28():125-44. PubMed ID: 2624171
[TBL] [Abstract][Full Text] [Related]
57. Biochemical basis for deoxyadenosine and 2-chlorodeoxyadenosine toxicity to resting human lymphocytes.
Seto S; Carrera CJ; Wasson DB; Carson DA
Adv Exp Med Biol; 1986; 195 Pt B():577-82. PubMed ID: 2876594
[No Abstract] [Full Text] [Related]
58. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines.
Carson DA; Kaye J; Matsumoto S; Seegmiller JE; Thompson L
Proc Natl Acad Sci U S A; 1979 May; 76(5):2430-3. PubMed ID: 313056
[TBL] [Abstract][Full Text] [Related]
59. 2-chlorodeoxyadenosine (2-CdA) does not change the expression of Fas antigen on chronic lymphocytic leukaemia cells.
Gora-Tybor J; Lech-Miranda E; Blonski JZ; Robak T
Adv Exp Med Biol; 2000; 486():307-10. PubMed ID: 11783506
[No Abstract] [Full Text] [Related]
60. Biochemical pharmacology and antitumor properties of 4-amino-8-[beta-D-ribofuranosylamino]pyrimido-[5,4-d]pyrimidine.
Jackson RC; Boritzki TJ; Cook PD; Hook KE; Leopold WR; Fry DW
Adv Enzyme Regul; 1989; 28():185-99. PubMed ID: 2560325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
